KPIs & Operating Metrics(New)
Adjusted Operating Income By Segment AnnualAdjusted Operating Margin By Segment Annual %BacklogBacklog AnnualBreakdown Of AssetsBusiness Unit Revenue Drug DevelopmentCapital ExpenditureContractual Obligations TotalCost Of RevenuesDepreciation And Amortization By SegmentEmployeeGoodwill By SegmentGross Margin %Gross ProfitIncome Before Income Taxes By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Income By SegmentOperating Margin By Segment %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant And Equipment, Net BreakdownProperty, Plant And Equipment, Net By GeographyProperty, Plant And Equipment, Net By SegmentQuarterly Net Order Drug DevelopmentRemaining Performance ObligationsRemaining Performance Obligations AnnualRevenue By Base Business Diagnostics RevenueRevenue By Business VerticalRevenue By Business Vertical %Revenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By PayerRevenue By Payer %Revenue By Payer AnnualRevenue By Payer Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue Mix Base Business Diagnostics Revenue %Revenue Per Employee %Revenuue Mix By Geography %Unearned Revenue
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Labcorp Holdings (LH) Gross Profit (2016 - 2025)

Labcorp Holdings' Gross Profit history spans 18 years, with the latest figure at $1.0 billion for Q1 2026.

  • On a quarterly basis, Gross Profit rose 6.94% to $1.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $4.1 billion, a 10.97% increase, with the full-year FY2025 number at $4.0 billion, up 10.71% from a year prior.
  • Gross Profit hit $1.0 billion in Q1 2026 for Labcorp Holdings, up from $993.2 million in the prior quarter.
  • Over the last five years, Gross Profit for LH hit a ceiling of $1.2 billion in Q1 2022 and a floor of $798.1 million in Q4 2022.
  • Historically, Gross Profit has averaged $933.8 million across 5 years, with a median of $904.4 million in 2024.
  • Biggest five-year swings in Gross Profit: crashed 36.04% in 2022 and later grew 13.35% in 2025.
  • Tracing LH's Gross Profit over 5 years: stood at $798.1 million in 2022, then rose by 2.92% to $821.4 million in 2023, then increased by 9.12% to $896.3 million in 2024, then rose by 10.81% to $993.2 million in 2025, then grew by 2.07% to $1.0 billion in 2026.
  • Business Quant data shows Gross Profit for LH at $1.0 billion in Q1 2026, $993.2 million in Q4 2025, and $1.0 billion in Q3 2025.